Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase-2 Study to Evaluate the Ability of HT-6184 to Attenuate Diagnostic Biomarkers of Post-procedure Acute Inflammation and Manage Pain Following Third Molar Extraction

Trial Profile

A Phase-2 Study to Evaluate the Ability of HT-6184 to Attenuate Diagnostic Biomarkers of Post-procedure Acute Inflammation and Manage Pain Following Third Molar Extraction

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HT-6184 (Primary)
  • Indications Inflammation; Pain
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Halia Therapeutics

Most Recent Events

  • 10 Sep 2024 According to a Halia media release, the company will present results from this trial at the upcoming 6th Inflammasome Therapeutics Summit taking place September 10-12, 2024, in Boston, MA
  • 18 Jul 2024 Status changed from recruiting to completed.
  • 17 Apr 2024 According to a Halia media release, the study will be presented at Asia BIO 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top